Inactive Instrument

Belluscura plc

BELL

GB00BD3B8Z11

Medical Equipment, Supplies & Distribution

Belluscura plc Announces Termination of Appointment of Simon Neicheril as Director, Effective May 2, 2025

Published on 09/22/2025

S&P Capital IQ

BELLUSCURA PLC

-.--%

Belluscura plc announced termination of appointment of MR SIMON NEICHERIL as Director, Effective May 2, 2025.

Latest news about Belluscura plc

01/10/25	EARNINGS: Next 15 profit falls; 4basebio and Mollyroe losses widen	AN
22/09/25	Belluscura plc Announces Termination of Robert Rauker as Director, Effective September 22, 2025	CI
22/09/25	Belluscura plc Announces Termination of Appointment of Richard John Piper as Director, Effective September 22, 2025	CI
22/09/25	Belluscura plc Announces Termination of Appointment of Simon Neicheril as Director, Effective May 2, 2025	CI
22/09/25	Belluscura Unit Cuts 15 US Jobs Amid Refinancing Talks	MT
22/09/25	Belluscura says proposed fundraising talks not yet concluded as anticipated	RE
12/09/25	Belluscura plc Announces Appointment of Guy Peters as Non-Executive Director, Effective September 11, 2025	CI
11/08/25	Metals One takes stake in CleanTech Lithium	AN
11/08/25	Belluscura to Potentially Dispose of Certain Medical Assets, Liabilities; Loan Note Deal Terminated	MT
30/06/25	EARNINGS AND TRADING: TT Electronics revenue falls; Capai in profit	AN
30/06/25	Belluscura Unit Obtains Short-term Convertible Loan Note	MT
30/06/25	Belluscura plc Provides Strategic Review Update	CI
26/05/25	Firms Scrap Forecasts Under Tariff Strain
16/05/25	Companies withdraw guidance amid Trump's tariffs	RE
13/05/25	Belluscura Says No New 'Notifiable Developments' as Shares Surge	MT

Belluscura PLC is a United Kingdom-based medical device developer company. The Company is focused on developing lightweight and portable oxygen enrichment technology. The Company's product X-PLOR, is a modular portable oxygen concentrator. The X-PLOR is lightweight, specifically designed to replace metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLOR can deliver up to 95% pure oxygen to patients 24 hours a day, seven days a week. The Company is focused on developing medical devices who suffer from chronic lung diseases, such as the Chronic Obstructive Pulmonary Disease (COPD), respiratory distress caused by COVID-19, and many other respiratory disorders. It is also focused on developing, licensing and manufacturing portable oxygen concentrators for use in treating lung diseases with its oxygen platform technologies, to include recreational and industrial oxygen concentrators, wound care devices, drug delivery devices and more.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company